- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02264938
Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation
October 9, 2014 updated by: Xavier Valldeperas, Germans Trias i Pujol Hospital
Drusen Morphology Changes in Nonexudative Age-related Degeneration Using Spectral Domain Optical Coherence Tomography After Oral Antioxidants Supplementation: One-year Results.
Purpose: To determine drusen morphology (volume and area) changes in nonexudative age-related macular degeneration (AMD) after one year of oral supplementation with AREDS-like formulation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Methods: Patients with AREDS category 2 and 3 AMD were prospectively enrolled in this study, and were randomized to receive daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid [DHA] 540mg + eicosapentaenoic acid [EPA] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg), or observation during one year.
ETDRS vision, biomicroscopy, intraocular pressure (IOP), color fundus photography and automatic measurement of drusen with Topcon 3D-OCT 2000 (Topcon, Tokyo, Japan) using the 6 x 6 mm 3D cube scan protocol, were performed in all patients, at baseline and 12 months after.
Automated delineation of macular drusen was modified by the investigators when evident segmentation errors occurred.
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- AREDS category 2 and 3 AMD
Exclusion Criteria:
- AREDS category 4 AMD
- other ophthalmological diseases
- currently on antioxidant supplementation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Observation
Patients with AREDS category 2 and 3 AMD are observed during 1 year
|
|
Active Comparator: Antioxidant
Patients with AREDS category 2 and 3 AMD are enrolled to take daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid [DHA] 540mg + eicosapentaenoic acid [EPA] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg) during 1 year.
|
Oral supplemmentation with antioxidants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Drusen volume change
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
July 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
October 9, 2014
First Submitted That Met QC Criteria
October 9, 2014
First Posted (Estimate)
October 15, 2014
Study Record Updates
Last Update Posted (Estimate)
October 15, 2014
Last Update Submitted That Met QC Criteria
October 9, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC-11-112
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Shanghai Refreshgene Technology Co., Ltd.RecruitingNeovascular Age-related Macular DegenerationChina
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
-
Olix Pharmaceuticals, Inc.Trial Runners, LLCRecruitingNeovascular Age-related Macular DegenerationUnited States
-
Seoul National University Bundang HospitalRecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
Clinical Trials on Antioxidant
-
Christopher GardnerNational Center for Complementary and Integrative Health (NCCIH)CompletedHypertension | Obesity | HyperlipidemiaUnited States
-
Addis Ababa UniversityUniversity of Oslo; Ullevaal University Hospital; Sorlandet Hospital HF; University...UnknownOxidative Stress | Liver Fibrosis | Schistosomiasis | Periportal FibrosisEthiopia
-
Showa UniversityIndonesia UniversityCompleted
-
Virginia Commonwealth UniversityCompletedMental Health DisordersUnited States
-
Penn State UniversityMcCormick Science InstituteCompletedPsychological Stress | CardiovascularUnited States
-
Unidad Temporal COVID-19 en Centro CitibanamexInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; Instituto...CompletedPneumonia, Viral | Covid19 | Oxidative Stress | ARDSMexico
-
IVI BilbaoAytu BioPharma, Inc.WithdrawnCompare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man)Spain
-
University of Ljubljana, Faculty of MedicineUniversity of LjubljanaCompleted
-
Acerta Pharma BVTerminatedDLBCL | Richter SyndromeUnited Kingdom, United States
-
University of TetovaUniversity of Tetova, Faculty of Medical SciencesCompletedInfertility | Male | OligoasthenozoospermiaNorth Macedonia